Literature DB >> 9524979

Comparison of the effects of zolpidem and flunitrazepam on sleep structure and daytime cognitive functions. A study of untreated unsomniacs.

K Dujardin1, J D Guieu, C Leconte-Lambert, P Leconte, P Borderies, B de La Giclais.   

Abstract

The effects of zolpidem 10 mg, flunitrazepam 1 mg, and placebo, administrated at bedtime, were studied in 12 healthy male insomniac patients. The assessments included polygraphic sleep recordings during the night and a battery of cognitive tests (sign crossing test, dichotic listening test, digit span test, visual recognition test and free recall test during four times during the following day. Compared with placebo, both active drugs improved sleep parameters. However, with zolpidem, the results were not statistically different from placebo. Zolpidem dit not alter sleep architecture in contrast to flunitrazepam, which significantly increased stage 2 and decreased slow wave sleep and REM sleep. No significant interaction was found between time of day for the evaluation of cognitive function. Flunitrazepam significantly impaired attention and memory compared with zolpidem and placebo, while zolpidem did not differ from placebo. These results indicate that zolpidem 10 mg preserved sleep structure and daytime cognitive functions in contrast to flunitrazepam.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9524979     DOI: 10.1055/s-2007-979289

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  8 in total

Review 1.  Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.

Authors:  K J Holm; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 2.  Zolpidem: a review of its use in the management of insomnia.

Authors:  Tracy Swainston Harrison; Gillian M Keating
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon.

Authors:  Mario Giovanni Terzano; Mariano Rossi; Vincenzo Palomba; Arianna Smerieri; Liborio Parrino
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

4.  Mild cognitive impairment: associations with sleep disturbance, apolipoprotein e4, and sleep medications.

Authors:  Shanna L Burke; Tianyan Hu; Christine E Spadola; Tan Li; Mitra Naseh; Aaron Burgess; Tamara Cadet
Journal:  Sleep Med       Date:  2018-09-20       Impact factor: 3.492

5.  Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo.

Authors:  Hervé Allain; Danièle Bentué-Ferrer; Antoine Tarral; Jean-Marc Gandon
Journal:  Eur J Clin Pharmacol       Date:  2003-05-17       Impact factor: 2.953

Review 6.  Comparative tolerability of newer agents for insomnia.

Authors:  Gary Zammit
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

7.  Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience.

Authors:  Takuma Matsumura; Jiro Terada; Chikara Yoshimura; Ken Koshikawa; Taku Kinoshita; Misuzu Yahaba; Kengo Nagashima; Seiichiro Sakao; Koichiro Tatsumi
Journal:  Drug Des Devel Ther       Date:  2019-02-28       Impact factor: 4.162

Review 8.  Sleep-related eating disorder associated with zolpidem: cases compiled from a literature review.

Authors:  Tiffany Ho; Alyssa Jimenez; Itzayana Sanchez; Christina Seeger; Merlyn Joseph
Journal:  Sleep Med X       Date:  2020-07-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.